Jürgen Schumacher
Director/Board Member at SCIENTIFIC INDUSTRIES, INC.
Net worth: 162 334 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Helena Santos | F | 59 | 30 years | |
Hans Werner Müller | M | - |
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | 23 years |
Stefan Fischer | M | 60 |
Algiax Pharmaceuticals GmbH
Algiax Pharmaceuticals GmbH BiotechnologyHealth Technology Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany.
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | 13 years |
Guido Koopmans | M | - |
Algiax Pharmaceuticals GmbH
Algiax Pharmaceuticals GmbH BiotechnologyHealth Technology Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany.
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | 13 years |
Robert P. Nichols | M | 63 | 26 years | |
John Moore | M | 59 | 5 years | |
Birgit Hasse | M | - |
Algiax Pharmaceuticals GmbH
Algiax Pharmaceuticals GmbH BiotechnologyHealth Technology Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany. | 13 years |
Ingo Lehrke | M | - |
Algiax Pharmaceuticals GmbH
Algiax Pharmaceuticals GmbH BiotechnologyHealth Technology Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany. | 5 years |
Karl D. Nowosielski | M | 46 | 10 years | |
Susanne Hermanns | M | - |
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | - |
Christopher Cox | M | 59 | 3 years | |
Birgit Thelen-Coco | F | - |
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | - |
Reginald Averilla | M | 46 | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Joseph Cremonese | M | 89 | 27 years | |
Reinhard Vogt | M | 66 | 2 years | |
Marcus Frampton | M | 44 | 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 9 | 56.25% |
Germany | 7 | 43.75% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jürgen Schumacher
- Personal Network